Thromb Haemost 2009; 102(03): 544-554
DOI: 10.1160/TH08-12-0830
Cardiovascular Biology and Cell Signalling
Schattauer GmbH

The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation

Bernhard Schweighofer
1   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
,
Julia Testori
1   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
,
Caterina Sturtzel
1   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
,
Susanne Sattler
1   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
,
Herbert Mayer
4   Present address: Austrian Science Foundation, Vienna, Austria
,
Oswald Wagner
2   Clinical Department for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna,Austria
3   Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Vienna, Austria
,
Martin Bilban
2   Clinical Department for Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna,Austria
3   Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Vienna, Austria
,
Erhard Hofer
1   Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received: 19 December 2008

Accepted after major revision: 01 June 2009

Publication Date:
22 November 2017 (online)

Summary

VEGF-A is the major trigger of vasculogenesis and physiologic angiogenesis. We have investigated to which extent the gene repertoire induced by VEGF-A in endothelial cells is distinct from that of other growth factors and inflammatory cytokines. Genes upregulated in human umbilical vein endothelial cells treated with VEGF, EGF or IL-1 were compared by microarray analysis and clusters characteristic for individual or combinations of inducers were defined. VEGF-A upregulated in comparison to EGF a five-fold larger gene repertoire, which surprisingly overlapped to 60% with the inflammatory repertoire of IL-1. As shown by real-time RT-PCR for selected genes, VEGFinduction was mostly mediated by VEGF receptor-2 and the capacity of VEGF-A to induce genes in common with IL-1 largely depended on activation of the calcineurin/NFAT pathway, since cyclosporin A inhibited this induction. Another angiogenic growth factor, bFGF, did not share a comparable induction of inflammatory genes, but partially induced a small group of genes in common with VEGF-A, which were not regulated by EGF. Thus, the data display that VEGF-A induces a distinct gene repertoire, which, contrasting with other growth factors such as EGF or bFGF, includes an inherent inflammatory component possibly contributing to the cross-regulation of angiogenesis and inflammation as further indicated by the VEGF-mediated induction of leukocyte adhesion. Furthermore, a small group of genes selectively induced by VEGF-A with potential importance for angiogenesis is defined.

 
  • References

  • 1 Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 09: 653-660.
  • 2 Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 09: 669-676.
  • 3 Gerhardt H, Golding M, Fruttiger M. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003; 161: 1163-1177.
  • 4 Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 09: 677-684.
  • 5 Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Rev 2004; 25: 581-611.
  • 6 Hiratsuka S, Minowa O, Kuno J. et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-9354.
  • 7 Shibuya M. Vascular endothelial growth factor receptor-2: its unique signalling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751-756.
  • 8 Fischer C, Mazzone M, Jonckx B. et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nature Rev 2008; 08: 942-956.
  • 9 Autiero M, Waltenberger J, Communi D. et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 09: 936-943.
  • 10 Hofer E, Schweighofer B. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 2007; 97: 355-363.
  • 11 Olsson AK, Dimberg A, Kreuger J. et al. VEGF receptor signalling – in control of vascular function. Nat Rev Mol Cell Biol 2006; 07: 359-371.
  • 12 Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 07: 505-516.
  • 13 Sini P, Wyder L, Schnell C. et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res 2005; 11: 4521-4532.
  • 14 Schabbauer G, Schweighofer B, Mechtcheriakova D. et al. Nuclear factor of activated T cells and early growth response-1 cooperate to mediate tissue factor gene induction by vascular endothelial growth factor in endothelial cells. Thromb Haemost 2007; 97: 988-997.
  • 15 Presta M, Dell’Era P, Mitola S. et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178.
  • 16 Compagni A, Wilgenbus P, Impagnatiello MA. et al. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000; 60: 7163-7169.
  • 17 Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 07: 803-815.
  • 18 Denk A, Goebeler M, Schmid S. et al. Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001; 276: 28451-28458.
  • 19 Winsauer G, de Martin R. Resolution of inflammation: intracellular feedback loops in the endothelium. Thromb Haemost 2007; 97: 364-369.
  • 20 Affymetrix Support Site. [ http://wwwaffymetrix-com/support/indexaffx ]
  • 21 Bilban M, Ghaffari-Tabrizi N, Hintermann E. et al. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 2004; 117: 1319-1328.
  • 22 Gene Expression Omnibus. [ http://www.ncbi.nlm.nih.gov/geo/]
  • 23 Primer3. [ http://primer3.sourceforge.net/ ]
  • 24 UCSC Genome Bioinformatics. [ http://genome.ucsc.edu/ ]
  • 25 EPCLUST (Expression Profile data CLUSTering and analysis). [ http://www.bioinf.ebc.ee/EP/EP/EP-CLUST/ ]
  • 26 Wu SQ, Minami T, Donovan DJ. et al. The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells. Blood 2002; 100: 4454-4461.
  • 27 Mayer H, Bilban M, Kurtev V. et al. Deciphering regulatory patterns of inflammatory gene expression from interleukin-1-stimulated human endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24: 1192-1198.
  • 28 Mechtcheriakova D, Schabbauer G, Lucerna M. et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signalling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. Faseb J 2001; 15: 230-242.
  • 29 Hesser BA, Liang XH, Camenisch G. et al. Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004; 104: 149-158.
  • 30 Minami T, Horiuchi K, Miura M. et al. Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem 2004; 279: 50537-50554.
  • 31 Sakurai Y, Ohgimoto K, Kataoka Y. et al. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc Natl Acad Sci USA 2005; 102: 1076-1081.
  • 32 Ho S, Clipstone N, Timmermann L. et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40-45.
  • 33 Waltenberger J, Claesson-Welsh L, Siegbahn A. et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-26995.
  • 34 Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006; 39: 469-478.
  • 35 Zetterstrom RH, Solomin L, Jansson L. et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997; 276: 248-250.
  • 36 Hermanson E, Borgius L, Bergsland M. et al. Neuropilin1 is a direct downstream target of Nurr1 in the developing brain stem. J Neurochem 2006; 97: 1403-1411.
  • 37 Safford M, Collins S, Lutz MA. et al. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 2005; 06: 472-480.
  • 38 Gallitano-Mendel A, Izumi Y, Tokuda K. et al. The immediate early gene early growth response gene 3 mediates adaptation to stress and novelty. Neuroscience 2007; 148: 633-643.
  • 39 Liu D, Evans I, Britton G. et al. The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis. Oncogene 2008; 27: 2989-2998.
  • 40 Lin Q, Lu J, Yanagisawa H. et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998; 125: 4565-4574.
  • 41 Shearman LP, Zylka MJ, Weaver DR. et al. Two period homologs: circadian expression and photic regulation in the suprachiasmatic nuclei. Neuron 1997; 19: 1261-1269.
  • 42 Chang KH, Chan-Ling T, McFarland EL. et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA 2007; 104: 10595-10600.
  • 43 Jackson JR, Seed MP, Kircher CH. et al. The codependence of angiogenesis and chronic inflammation. Faseb J 1997; 11: 457-465.
  • 44 Anderson GD, Hauser SD, McGarity KL. et al. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-2679.
  • 45 Ley K, Laudanna C, Cybulsky MI. et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 07: 678-689.
  • 46 Cavallaro U, Liebner S, Dejana E. Endothelial cadherins and tumor angiogenesis. Exp Cell Res 2006; 312: 659-667.
  • 47 Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993; 11: 767-804.
  • 48 Shah G, Middleton FA, Gentile KL. et al. Cyclosporine inhibition of angiogenesis involves the transcription factor HESR1. J Surg Res 2008; 149: 171-176.
  • 49 Aerts S, Thijs G, Coessens B. et al. Toucan: deciphering the cis-regulatory logic of coregulated genes. Nucleic Acids Res 2003; 31: 1753-1764.
  • 50 Chai J, Jones MK, Tarnawski AS. Serum response factor is a critical requirement for VEGF signalling in endothelial cells and VEGF-induced angiogenesis. Faseb J 2004; 18: 1264-1266.
  • 51 Wolfe SA, Zhou P, Dotsch V. et al. Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc. Nature 1997; 385: 172-176.
  • 52 Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 2005; 436: 193-200.